Hematological clozapine monitoring with a point-of-care device: A randomized cross-over trial

European Neuropsychopharmacology

Volumn 22, Issue 6, 2012, Pages 401-405

  Nielsen, Jimmi ^a   Thode, Dorrit ^a   Stenager, Elsebeth ^b   Andersen, Kristian Øllegaard ^b   Sondrup, Ulla ^c   Hansen, Tine N ^c   Munk, Anne Marie ^d   Lykkegaard, Signe ^d   Gosvig, Annette ^e   Petrov, Igor ^f   Le Quach, Phuong ^f  

^a AALBORG UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Psychiatric Centre Greve   (Denmark)

^e Psychiatric Department Esbjerg Ribe   (Denmark)

^f Mental Health Services CPH   (Denmark)

Author keywords

Agranulocytosis; Clozapine; Hematological monitoring; Neutropenia; Point of care device; Schizophrenia

Indexed keywords

CLOZAPINE;

ADULT; ARTICLE; BLOOD SAMPLING; CAPILLARY BLOOD; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; GRANULOCYTE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; BLOOD SPECIMEN COLLECTION; CLOZAPINE; CROSS-OVER STUDIES; FEMALE; HEMATOLOGY; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL DISORDERS; MIDDLE AGED; PAIN MEASUREMENT; QUESTIONNAIRES;

EID: 84860475747     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2011.10.001     Document Type: Article

References (22)

1. Alphs L., Anand R., Islam M.Z., Meltzer H.Y., Kane J.M., Krishnan R., Green A.I., Potkin S., Chouinard G., Lindenmayer J.P., Kerwin R. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophr. Bull. 2004, 30:577-586.
2. Atkin K., Kendall F., Gould D., Freeman H., Liberman J., O'Sullivan D. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br. J. Psychiatry 1996, 169:483-488.
3. Atkinson J.M., Douglas-Hall P., Fischetti C., Sparshatt A., Taylor D.M. Outcome following clozapine discontinuation: a retrospective analysis. J. Clin. Psychiatry 2007, 68:1027-1030.
4. Barnes T.R. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J. Psychopharmacol. 2011, 25:567-620.
5. Ciapparelli A., Dell'Osso L., Bandettini di Poggio A., Carmassi C., Cecconi D., Fenzi M., Chiavacci M.C., Bottai M., Ramacciotti C.E., Cassano G.B. Clozapine in treatment-resistant patients with schizophrenia, schizoaffective disorder, or psychotic bipolar disorder: a naturalistic 48-month follow-up study. J. Clin. Psychiatry 2003, 64:451-458.
6. Citrome L., Volavka J., Czobor P., Sheitman B., Lindenmayer J.P., McEvoy J., Cooper T.B., Chakos M., Lieberman J.A. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 2001, 52:1510-1514.
7. Conley R.R., Kelly D.L., Richardson C.M., Tamminga C.A., Carpenter W.T. The efficacy of high-dose olanzapine versus clozapine in treatment-resistant schizophrenia: a double-blind crossover study. J. Clin. Psychopharmacol. 2003, 23:668-671.
8. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45:789-796.
9. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 2006, 163:600-610.
10. Miodownik C., Lerner V., Kibari A., Toder D., Cohen H. The effect of sudden clozapine discontinuation on management of schizophrenic patients: a retrospective controlled study. J. Clin. Psychiatry 2006, 67:1204-1208.
11. Nielsen J., Meyer J.M. Risk factors for ileus in patients with schizophrenia. Schizophr. Bull. 2010, 2010 Nov 26 (Electronic publication ahead of print).
12. Nielsen J., Foldager L., Meyer J.M. Increased use of antibiotics in patients treated with clozapine. Eur. Neuropsychopharmacol. 2009, 19:483-486.
13. Nielsen J., Dahm M., Lublin H., Taylor D. Psychiatrists' attitude towards and knowledge of clozapine treatment. J. Psychopharmacol. 2010, 24:965-971.
14. Nielsen J., Skadhede S., Correll C.U. Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naive schizophrenia patients. Neuropsychopharmacology 2010, 35:1997-2004.
15. Nielsen J., Damkier P., Lublin H., Taylor D. Optimizing clozapine treatment. Acta Psychiatr. Scand. 2011, 123:411-422.
16. Nielsen J., Graff C., Kanters J.K., Toft E., Taylor D., Meyer J.M. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011, 25:473-490.
17. Nooijen P.M., Carvalho F., Flanagan R.J. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum. Psychopharmacol. 2011, 26:112-119.
18. Perkins S.L. Normal Blood and Bone Marrow Values in Humans, Wintrobe's Clinical Hematology 2003, Lippincott & Wilkins Publishers Lippincott & Wilkins Publishers. 11th edn.
19. Pollack S., Woerner M.G., Howard A., Fireworker R.B., Kane J.M. Clozapine reduces rehospitalization among schizophrenia patients. Psychopharmacol. Bull. 1998, 34:89-92.
20. Taylor D.M., Young C., Paton C. Prior antipsychotic prescribing in patients currently receiving clozapine: a case note review. J. Clin. Psychiatry 2003, 64:30-34.
21. Whiskey E., Taylor D. Restarting clozapine after neutropenia: evaluating the possibilities and practicalities. CNS Drugs 2007, 21:25-35.
22. Whiskey E., Wykes T., Duncan-McConnell D., Haworth E., Walsh N., Hastilow S. Continuation of clozapine treatment: practice makes perfect. Psychiatr. Bull. 2003, 27:211-213.